NL-OMON40906已完成4 期
Iron absorptiontrail after Roux- en -Y Gastric Bypass - Ironabsorption trial
Rijnstate Ziekenhuis0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients who are eligible for a primary Roux- en -Y gastric bypass and have no pre-existing iron deficiency (serum ferritin of 20-200 micrograms / L), age between 18-65 years.
排除标准
- •-bloodtransfusion one month before and in the study period
- •-the use of ironcontaining nutritional supplements, except our standardized multivitamin supplements.;-decreased function of the kidney with a GFR of < 30ml/min and/or serum kreatinin below 50micromol/L;-Hb < 7,4 mmol/L in females and Hb < 8.4mmol/L in males;-accumulation of iron;- iron diseases;- hypersensitivity for one of the medicinal products ;- psychiatric illness;-pregnancy
研究者
相似试验
招募中
不适用
Additive effect of Roux-en Y Gastric Bypass to preoperative Very low calorie diet on non-alcoholic fatty liver diseases (NAFLD, NASH)-A randomized controlled trialK75.8E66.0Other specified inflammatory liver diseasesObesity due to excess caloriesDRKS00027810Chirurgische Klinik Universitätsmedizin Mannheim150
招募中
不适用
Faecal reference values after Roux-en-Y gastric bypassgastric bypass10017969NL-OMON40926Slotervaartziekenhuis120
招募中
4 期
The effect of Roux-en-Y Gastric Bypass surgery in morbidly obese patients on pharmacokinetic of lansoprazoleMorbidly ObesityRoux-en-y Gastric bypass, Lansoprazole, PharmacokineticsTCTR20220118001Ratchadapisek Sompoch Endowment Fund Chulalongkorn university16
进行中（未招募）
1 期
Study of blood concentrations of morphine after oral administration of immediate release morphine in subject who have undergone a bariatric surgery called Roux-en-Y Gastric Bypass for a long time, in comparison with subjects who did not undergo surgery.EUCTR2016-001143-40-FRTherapeutic Research Unit
招募中
不适用
The effects of the Laparoscopic Roux-en-Y Gastric Bypass and the Laparoscopic Mini Gastric Bypass on the remission of type 2 Diabetes Mellitus and the pathophysiological mechanisms that drive the conversion of malign to benign obesitytype 2 diabetes mellitus100184241001794310019654obesityNL-OMON50364Academisch Medisch Centrum220